2025可持续全球领导者大会于10月16日-18日在上海市黄浦区世博园区召开。 克罗地亚共 和国第四任总统、国际奥委会委员基塔罗维奇（Kolinda Grabar-Kitarović），华熙集团董事长赵 燕，前中国女排运动员、奥运冠军赵蕊蕊，人文财经观察家秦朔共同探讨"破界者：国际舞台 的女性领导力"。 领导力不是说谁的声音大谁就获胜 克罗地亚共和国第四任总统、国际奥委会委员科琳达·格拉巴尔—基塔罗维奇（Kolinda Grabar-Kitarović ）表示， 人们总是会去对比女性和男性的能力，有的时候是公平的，有 的时候是不公的，但是我们必须要有一席之地。我们可以把独特的能力带上谈判桌，因为女 性善于建立联盟善于倾听，善于连接，善于建立谈判的信任，所以永远不要接受否定的答 案，但是我们需要建立起自己的韧性，领导力并不是说谁的声音大谁就是获胜，而是关于谁 能提出最具建设性的意见，以及谁能够真正弥合差异，凝聚共识。 此外，她还特别强调了体育在加速可持续创新方面的独特价值。作为全球供应链的一环，体 育能凝聚政治分歧、激发合作与变革。现代奥运会已超越国家荣誉，成为一项承载社会经济 与环境价值的"全球使命"。通过奥 ...

证券之星消息，10月17日医疗美容板块较上一交易日下跌2.52%，锦波生物领跌。当日上证指数报收于 3839.76，下跌1.95%。深证成指报收于12688.94，下跌3.04%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.46 | 0.29% | 15.33万 | 5280.26万 | | 688363 | 华熙生物 | 53.23 | -2.31% | 2.68万 | 1.45 Z | | 300896 | 爱美客 | 169.55 | -2.88% | 3.11万 | 5.33 乙 | | 920982 | 锦波生物 | 270.32 | -3.86% | 1.11万 | 3.03亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出8494.02万元，游资资金净流出1029.23万元，散户 资金净流入9523.26万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 主力净流入（元） 主力净占比 游资 ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structures and transforming economic models. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper outlines the development status and trends of biomanufacturing, analyzing the global landscape and key platform facilities [5]. - It compares the biomanufacturing sectors of China and the United States, identifying competitive advantages and areas for improvement [5]. - Future development trends in biomanufacturing are discussed, indicating a shift towards more integrated and innovative approaches [5]. Group 2: Policy Landscape - The report reviews major policies affecting biomanufacturing both domestically and internationally, providing insights into regulatory frameworks that shape the industry [5]. - It categorizes foreign and domestic policies, highlighting their implications for the growth of the biomanufacturing sector [5]. Group 3: Industry Map and Applications - A comprehensive map of the Chinese biomanufacturing industry is presented, detailing key players and their roles [5]. - The report identifies critical application areas for biomanufacturing, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises and Investment Landscape - The white paper lists the top 10 leading enterprises in China's biomanufacturing sector, showcasing their contributions and market positions [6]. - It also summarizes the strategic directions of 15 publicly listed companies in synthetic biology, along with their investment and development strategies [6]. Group 5: Challenges and Recommendations - The report discusses the challenges faced by the biomanufacturing industry in China, including technological, regulatory, and market-related issues [6]. - Targeted policy recommendations are provided to address these challenges and promote sustainable growth in the biomanufacturing sector [6].

赵燕表示华熙生物的使命是让每个生命都是鲜活的，提高生命质量、延长生命长度。"我们从看不见的 微观世界出发，致力于让每一个生命都能更健康、更长久地绽放。让人能够健康，能蹦能跳，能吃能睡 的活到超过120岁。" 10月17日上午，华熙集团董事长、华熙生物董事长兼总裁赵燕女士亮相2025可持续全球领导者大会。 专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 ...

谈及华熙生物，离不开玻尿酸、透明质酸。赵燕指出，透明质酸原来需要从动物机关里提取，我们掌握 了全球先进的合成生物技术和酶切法，才能够像基因代码一样，改变微生物、管理微生物、让微生物为 我们工作，高效地获得我们所需要的各种物质。 "这些工具并非我们凭空地创造出来的，而是我们学习了大自然亿万年的进化法则"。最早我们筛选微生 物就用了两年时间，而如今借助技术进步，构建所需微生物的时间已缩短至两小时。"这就是今天世界 的变化，但是我们要对生命敬畏，我们才能找到它的规律"。 赵燕将华熙生物的成长视为中国乃至亚洲制造业崛起与升华的缩影。她表示，这一代亚洲企业是全球化 的受益者，通过改革开放承接全球科学分工，从最基础的制造业起步，实现了从"执行者"到"同行者"， 再到"探索者"的蜕变。 专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 10月17日上午，华熙集团董事长、华熙生物董事长兼总裁赵燕女士亮相2025可持续全球领导者大会。 赵燕以创业者身份分享了她的两段核心经历。其一是打造北京华熙LIVE五棵松这一文商旅体创新聚集 体，她指出，其核心在于"用内容驱动场景，场景创造价值"，最终目的是让人感受到快乐， ...

专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 10月17日上午，华熙集团董事长、华熙生物董事长兼总裁赵燕女士亮相2025可持续全球领导者大会。 赵燕现场分享了她的两段创业经历。其一是打造北京华熙LIVE五棵松这一文商旅体创新聚集体，她指 出，其核心在于"用内容驱动场景，场景创造价值"，最终目的是让人感受到快乐，因为快乐而美丽，因 为美丽而健康。其二是广为人知的华熙生物，公司致力于通过衰老干预和组织再生，为人类生命健康提 供全面解决方案。她强调，这两家企业共同服务于"健康、美丽、快乐"这六个字。"让每个生命都是鲜 活的"是赵燕赋予企业的使命。 ...

专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 10月17日上午，华熙集团董事长、华熙生物董事长兼总裁赵燕女士亮相2025可持续全球领导者大会并发 表演讲。 责任编辑：杨赐 赵燕表示，华熙生物的成长是中国乃至亚洲制造业崛起与升华的一个缩影。她指出，企业的成长历程与 中国生物制造行业乃至整个中国制造业的发展同频共振。 "我们这一代亚洲企业是全球化的受益者"。通过改革开放，我们承接了全球的科学分享与分工协作，从 最基础的制造业起步，将制造能力做到强大。在此基础上，我们得以接触前沿研发，窥探生命密码，理 解科学背后的逻辑，实现了从"执行者"到"同行者"，再到"探索者"的蜕变。 赵燕强调，今天的亚洲制造业已不仅仅是"世界工厂"，更是全新全球网络中不可或缺的一环。华熙生物 以及众多从制造业崛起的中国企业，正在向研发和品牌的高地攀登，努力拓展微笑曲线的两端。这是一 个充满期待的旅程。 ...

专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2025可持续全球领导者大会于10月16日-18日在上海市黄浦区世博园区召开。 本届可持续大会在以往四届"ESG全球领导者大会"的基础上进一步升级！嘉宾阵容强大，可持续大会组 委会邀请约500位中外重磅嘉宾，其中约100位为海外嘉宾，不仅有政要、前政要、国际组织的代表，还 包括了诺贝尔奖得主、图灵奖得主、全球500强企业负责人等国际顶尖学者与业界领军代表。 华熙集团董事长、华熙生物董事长兼总裁赵燕出席2025可持续全球领导者大会并参与圆桌对话。 责任编辑：杨赐 2025可持续全球领导者大会由世界绿色设计组织（WGDO）与新浪集团联合主办，国际财务报告准则 基金会（IFRS Foundation）北京办公室协办，新浪财经与世界绿色设计组织北京代表处承办，上海市黄 浦区人民政府支持。大会以"携手应对挑战：全球行动、创新与可持续增长"为核心主题，汇聚全球智慧 力量，共探可持续发展新路径，为全球可持续治理注入澎湃的"中国动能"。 ...

Core Insights - The domestic medical beauty market in China is becoming increasingly competitive, with significant price reductions and patent disputes among leading companies [1][3][6] - Major players are expanding overseas as domestic profit margins shrink, indicating a strategic shift towards international markets [1][11] Market Competition - New Oxygen launched a low-priced "Miracle Youth Needle" at 2999 yuan, significantly undercutting competitors and causing dissatisfaction among upstream material suppliers [3][6] - Huaxi Biological and Juzi Biological are engaged in a fierce dispute over collagen product patents, highlighting the intense competition in the market [3][4] - The competition is characterized by a shift from regulatory competition to market-driven competition, with a growing number of brands entering the space [6][7] Financial Performance - Major companies like Aimeike and Huaxi Biological reported significant declines in revenue and net profit, with Aimeike's revenue and net profit down 21.59% and 29.57% respectively in the first half of the year [7][10] - Huaxi Biological's revenue and net profit also fell by 19.57% and 35.38% respectively, marking a continuous decline over two years [7][10] International Expansion - Chinese medical beauty companies are increasingly looking to international markets, with firms like Aimeike and Huaxi Biological investing in overseas partnerships [1][11] - The strategy involves acquiring or investing in foreign companies to introduce Chinese products to international markets, rather than relying on traditional business development methods [11][12] Emerging Markets - There is a growing opportunity in emerging markets such as Southeast Asia and Latin America, where demand for cost-effective and multifunctional products is rising [12][13] - Companies are focusing on building technological barriers and moving away from the "low-price" label by investing in advanced materials and techniques [13]

Core Insights - The Chinese medical aesthetics market is becoming increasingly competitive, with significant price reductions and patent disputes among leading companies [1][2][3] - Major players are expanding internationally as domestic competition intensifies, with companies like Four Rings Pharmaceutical investing in overseas markets [1][9] - The industry is transitioning from a focus on product registration to market-driven competition, leading to a "price war" and a shift towards a more comprehensive competition model involving product, service, and technology [6][10] Market Dynamics - The medical aesthetics industry in China has evolved from a niche market to a significant sector, but the penetration rate of medical aesthetics products remains low compared to mature markets like Europe and the U.S. [1][6] - New Oxygen's introduction of the "Miracle Youth Needle 3.0" at a price point below 3000 yuan marks a significant price drop in the domestic market [1][2] - The competition among major products such as water light needles, youth needles, and recombinant collagen is intensifying, with numerous new products entering the market [4][6] Financial Performance - Leading companies are experiencing significant revenue declines, with Aimeike reporting a 21.59% drop in revenue and a 29.57% decrease in net profit in the first half of the year [7][8] - Huaxi Biological has also seen a continuous decline in annual performance, with a 19.57% drop in revenue and a 35.38% decrease in net profit in the first half of the year [7][8] International Expansion - Chinese medical aesthetics companies are increasingly looking to international markets for growth, with several firms, including Aimeike and Huaxi Biological, investing in overseas companies [9][10] - The global medical aesthetics market is still in a growth phase, but companies face challenges such as regulatory differences, cultural adaptation, and established local competition [10][12] - Emerging markets in Southeast Asia, the Middle East, and Latin America present opportunities for Chinese companies to expand, as these regions show rapid growth in medical aesthetics consumption [12][13]